Spyre Therapeutics opened lower at $96.78, compared with its previous close of $98.96. In the last trading session, the stock traded between $95.39 and $98.96. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Spyre Therapeutics is now worth
$ 659.03
giving a profit of
$ 559.03 (559.03%)
Note: Past profits do not guarantee future returns.
Rating from 14 Analysts
Today's Change
$-3.40 (-3.44%)
Day High
$98.96
Day Low
$95.39
Day Open
$96.78
Prev Close
$98.96
Volume
2,71,672
1W Return
3.52%
1M Return
12.72%
3M Return
-2.31%
6M Return
32.93%
1Y Return
301.01%
Market Cap ($ Mn)
8,819
PE Ratio
-
PB Ratio
8.34
PEG Ratio
-
ROE
-42.01%
ROCE
-33.52%
EPS (TTM)
$-0.41
1 Week
3.52%
1 Month
12.72%
3 Months
-2.31%
6 Months
32.93%
9 Months
184.57%
BTIG reiterates Buy rating on Spyre Therapeutics with $121 target
BTIG reiterates a Buy rating on Spyre Therapeutics. Price target maintained at $121 per share. Analyst Julian Harrison leads the coverage recommendation.
10 days agoSpyre Therapeutics prices $350M offering at $85 per share
Priced public offering at $85.00 per share. Raised approximately $350.0 million in gross proceeds. Sold 4,117,648 common shares. Funds to advance SPY072 for hidradenitis suppurativa. Underwriters have option for additional $52.5 million.
24 days agoSpyre Therapeutics grants inducement awards to two employees
Approved 21,424 stock options and 6,604 RSUs for two non-executive employees. Stock options have an exercise price of $89.93 and a 10-year term. Awards were granted under the 2018 Equity Inducement Plan per Nasdaq rules. Options vest over four years; RSUs vest on quarterly calendar anniversaries.
27 days agoBTIG reiterates Buy on Spyre Therapeutics, holds $121 target
BTIG reiterated a Buy rating on Spyre Therapeutics. Price target maintained at $121 per share. Analyst Julian Harrison issued the rating update.
29 days agoSpyre Therapeutics grants equity inducement awards to employee
Spyre Therapeutics granted 2,106 stock options and 745 RSUs to a non-executive employee. Stock options carry an exercise price of $88.50, matching the Sept 1 closing price. Awards vest over time based on continuous service, with options having a 10-year term. Grants were approved under the 2018 Equity Inducement Plan to secure employment.
1mo agoSpyre Therapeutics RA data misses internal bar; shares fall 12%
Spyre Therapeutics reported Phase 2 RA data for SPY072 showing statistical significance but missing internal monotherapy thresholds. Shares fell 12.33% to $94.12 following the disclosure that efficacy did not meet the bar for prioritization. Low dose showed significant benefit on primary endpoint DAS28-CRP vs placebo at Week 12. High dose showed nominal significance on secondary ACR20 endpoint; low dose on exploratory ACR50. Company maintains focus on combination therapies and other autoimmune indications.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 3 years ago in Spyre Therapeutics is now worth
$ 659.03
giving a profit of
$ 559.03 (559.03%)
Note: Past profits do not guarantee future returns.
